FDA Safety Communication: New Monitoring Requirements for Cardiovascular Drug Trials

Summary

The FDA has issued a safety communication requiring enhanced cardiac monitoring in all Phase II and Phase III trials involving cardiovascular agents. New requirements mandate continuous telemetry for the first 72 hours post-dose, mandatory troponin monitoring at specified intervals, and independent DSMB review of all cardiac events within 48 hours of occurrence. Applies to all active INDs.